Company intelligence / Profile preview

Connect Therapeutics

San Diego, California, United Statesconnecttherapeutics.com ↗

Ownership: Private
Employees: ~62
Development stage: Commercial

Overview

Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for inflammatory diseases. Its lead asset, rademikibart, has shown rapid and sustained improvement in pulmonary function for asthma patients in Phase 2 trials. The company plans to initiate parallel Phase 2 studies of rademikibart as adjunct therapy for acute exacerbations of asthma and COPD in mid‑2025. Other pipeline assets include small molecules targeting ulcerative colitis and pruritus associated with skin inflammation[5].

Therapeutic areas: PulmonologyDermatologyGastroenterology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Simcere Pharmaceutical Group – holds greater China rights to rademikibart

Beyond the preview

Go deeper on Connect Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Connect Therapeutics.

Explore the full profile